Clinical trials: 65 Years Older
Erectile Dysfunction
Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.
This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile…
- Trial name
- NCT00655629
- Testing
- Vardenafil ODT (STAXYN, BAY38-9456)
- Where
- 40 sites in United States, Australia and 2 more
- Volunteers
- 339 people
- Sponsor
- Bayer
Influenza
Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects
The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing process of three consecutive lots of…
- Trial name
- NCT01162122
- Testing
- MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV)
- Where
- 38 sites in United States, Colombia and 2 more
- Volunteers
- 7,109 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Respiratory Syncytial Viruses, Respiratory Tract Diseases
A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
The purpose of this study is to demonstrate the efficacy of active study vaccine in the prevention of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed respiratory syncytial virus (RSV)-mediated lower respiratory…
- Trial name
- CYPRESS (NCT03982199)
- Testing
- RSV Vaccine
- Where
- 40 sites in United States
- Volunteers
- 5,815 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)
This study is designed to assess the safety, tolerability, and immunogenicity of V114 compared with Prevnar 13™ in healthy adults 65 years of age or older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
- Trial name
- NCT02573181
- Testing
- V114, Prevnar 13™
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
The purpose of this study is to comply with the post marketing condition to the exceptional approval of Arepanrix™ in Japan and to assess the immunogenicity and safety of GSK Biologicals' H1N1 influenza vaccine healthy Japanese…
- Trial name
- NCT01114620
- Testing
- Arepanrix™
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis, Tetanus
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
It is well recognized that older adults can contract pertussis, suffer its complications, and unwittingly transmit it to close contacts, which may well include infants too young to have received their primary series of DTaP…
- Conditions
- Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00457249
- Testing
- ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
- Where
- 19 sites in United States
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older
The purpose of this study is to evaluate the efficacy of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older.
- Trial name
- NCT00753272
- Testing
- GSK Bio's influenza vaccine GSK2186877A, Fluarix TM
- Where
- 274 sites in United States, Belgium and 13 more
- Volunteers
- 43,695 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
Primary Objective: To provide serum samples (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to Center for Biologics Evaluation and Research (CBER) for further…
- Trial name
- NCT04551677
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults
The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (>=)18…
- Trial name
- NCT05975840
- Testing
- FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, FLU Q-PAN H5N8 750_B
- Where
- 20 sites in United States
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a…
- Trial name
- NCT05648357
- Testing
- Fluarix Tetra Vaccine
- Where
- 6 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to determine the safety and effectiveness of pracinostat when combined with azacitadine for patients who are 65 years of age or older and have Acute Myelogenous Leukemia (AML)
- Trial name
- NCT01912274
- Testing
- Pracinostat, Azacitidine
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Helsinn Healthcare SA
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)
- Trial name
- NCT01724346
- Testing
- Ibrutinib, Next-line ibrutinib
- Where
- 88 sites in United States, Australia and 14 more
- Volunteers
- 269 people
- Sponsor
- Pharmacyclics LLC.
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
The primary objective of the study was to provide sera (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to the Center for Biologics Evaluation and Research (CBER) for…
- Trial name
- GRC00097 (NCT04109222)
- Testing
- Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Prophylaxis of A/H3N2v Influenza
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in children ages 3 to <9 years, adolescents 9 to <18 years, adults 18 to <65 years and elderly 65 years and older.
- Trial name
- NCT01855945
- Testing
- Swine Influenza
- Where
- 11 sites in United States
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) does not induce lower antibody…
- Trial name
- Engage (NCT06134804)
- Testing
- ExPEC9V, HD quadrivalent influenza vaccine
- Where
- 41 sites in United States, Belgium and 2 more
- Volunteers
- 959 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Influenza (Healthy Volunteers)
Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older
Primary Objective: To demonstrate the superior relative effectiveness of QIV-HD as compared to QIV-SD among persons 65 years of age and older for the prevention of cardiovascular and/or respiratory hospitalizations.
- Trial name
- NCT04137887
- Testing
- Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD), Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)
- Where
- Finland
- Volunteers
- 33,096 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
A Phase 2 trial to confirm the dose and formulation, demonstrate adjuvant effect, and evaluate the safety and tolerability of a single intramuscular injection of Quad-NIV with or without Matrix-M1 adjuvant in healthy adults ≥ 65…
- Trial name
- NCT03658629
- Testing
- NanoFlu (Quad-NIV), Matrix-M Adjuvant, Fluzone HD
- Where
- 14 sites in United States
- Volunteers
- 1,375 people, healthy volunteers welcome
- Sponsor
- Novavax
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic…
- Trial name
- NCT01722487
- Testing
- Ibrutinib, Chlorambucil
- Where
- 108 sites in United States, Australia and 14 more
- Volunteers
- 269 people
- Sponsor
- Pharmacyclics LLC.
Virus Diseases, RNA Virus Infections
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03739112
- Testing
- Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 12,794 people, healthy volunteers welcome
- Sponsor
- Medicago